Moreover, in clinical trials of venetoclax, the ratios of Bcl-2/Mcl-1 and Bcl-2/Bcl-xL transcripts correlated to a greater degree than the level of Bcl-2 mRNA alone with efficiency of venetoclax in multiple myeloma patients [46]. This evidence concerns the gene BCL2 and plasma cell myeloma.